These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 32856728)
1. Management of SARS-CoV-2 pneumonia. Sagnelli C; Celia B; Monari C; Cirillo S; De Angelis G; Bianco A; Coppola N J Med Virol; 2021 Mar; 93(3):1276-1287. PubMed ID: 32856728 [TBL] [Abstract][Full Text] [Related]
2. A review of medications used to control and improve the signs and symptoms of COVID-19 patients. Hushmandi K; Bokaie S; Hashemi M; Moghadam ER; Raei M; Hashemi F; Bagheri M; Habtemariam S; Nabavi SM Eur J Pharmacol; 2020 Nov; 887():173568. PubMed ID: 32956644 [TBL] [Abstract][Full Text] [Related]
3. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H Elife; 2020 Apr; 9():. PubMed ID: 32338605 [TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. Schijns V; Lavelle EC Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473 [TBL] [Abstract][Full Text] [Related]
5. The Antiviral, Anti-Inflammatory Effects of Natural Medicinal Herbs and Mushrooms and SARS-CoV-2 Infection. Shahzad F; Anderson D; Najafzadeh M Nutrients; 2020 Aug; 12(9):. PubMed ID: 32854262 [TBL] [Abstract][Full Text] [Related]
6. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?]. Nisole S; Saulnier A; Gatignol A Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548 [No Abstract] [Full Text] [Related]
7. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
8. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. Gallelli L; Zhang L; Wang T; Fu F J Clin Pharmacol; 2020 Jul; 60(7):815-825. PubMed ID: 32441805 [TBL] [Abstract][Full Text] [Related]
9. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711 [TBL] [Abstract][Full Text] [Related]
10. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Lisi L; Lacal PM; Barbaccia ML; Graziani G Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969 [TBL] [Abstract][Full Text] [Related]
12. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application. Contini C; Enrica Gallenga C; Neri G; Maritati M; Conti P Med Hypotheses; 2020 Nov; 144():109876. PubMed ID: 32562915 [TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. Hosoki K; Chakraborty A; Sur S J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257 [TBL] [Abstract][Full Text] [Related]
14. Coronavirus Disease-2019 (COVID-19): An Updated Review. Rudrapal M; Khairnar SJ; Borse LB; Jadhav AG Drug Res (Stuttg); 2020 Sep; 70(9):389-400. PubMed ID: 32746481 [TBL] [Abstract][Full Text] [Related]
15. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Sharma A; Tiwari S; Deb MK; Marty JL Int J Antimicrob Agents; 2020 Aug; 56(2):106054. PubMed ID: 32534188 [TBL] [Abstract][Full Text] [Related]
16. Pathogenesis-directed therapy of 2019 novel coronavirus disease. Stratton CW; Tang YW; Lu H J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355 [TBL] [Abstract][Full Text] [Related]
17. Perspective: The Potential Effects of Naringenin in COVID-19. Alberca RW; Teixeira FME; Beserra DR; de Oliveira EA; Andrade MMS; Pietrobon AJ; Sato MN Front Immunol; 2020; 11():570919. PubMed ID: 33101291 [TBL] [Abstract][Full Text] [Related]